Outlook Therapeutics, Inc. Operating Income Loss

• Outlook Therapeutics, Inc. showed an increase of +6.5% in Operating Income Loss from 2024 to 2025.
• This data is from Outlook Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on December 19, 2025.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 11 years of available data (2015 to 2025), Outlook Therapeutics, Inc.'s Operating Income Loss has declined by 44.0%.
• Historical annual values: Fiscal year 2025: -$67.06 million | Fiscal year 2024: -$71.70 million | Fiscal year 2023: -$53.13 million | Fiscal year 2022: -$63.07 million | Fiscal year 2021: -$51.73 million | Fiscal year 2020: -$36.84 million | Fiscal year 2019: -$36.30 million | Fiscal year 2018: -$29.64 million | Fiscal year 2017: -$35.88 million | Fiscal year 2016: -$51.35 million | Fiscal year 2015: -$46.56 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026